Orelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma

3-months CR rate

the ratio of numbers of patients with complete response to all the participants

Time frame: up to 3 months

2-year progression-free survival (PFS)

the period from the date of patients sign informed consent to the observed progression of the disease or the occurrence of death for any reason

Time frame: From date of patients sign informed consent until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years

2-year event-free survival (EFS)

the period from the date of patients sign informed consent to the observed event for any reason

Time frame: From date of patients sign informed consent until the date of first documented event, progression or date of death from any cause, whichever came first, assessed up to 2 years

2-year overall survival rate

time between the date of patients sign informed consent and the date of death or the date of last follow-up time

Time frame: From date of patients sign informed consent until the date of death or the date of last follow-up time, whichever came first, assessed up to 2 years

Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

Record the name of adverse events and number of participants with treatment-related adverse events as assessed by CTCAE v5.0

Time frame: Throughout the treatment period, up to 6 months